CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $179.2 million in its second quarter.
The Cambridge, Massachusetts-based company said it had a loss of $1.56 per share.
The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $1.79 per share.
The RNA interference drug developer posted revenue of $104 million in the period, which also beat Street forecasts. Six analysts surveyed by Zacks expected $98.7 million.
Alnylam shares have increased 27% since the beginning of the year. The stock has more than doubled in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY
Automated Insights, source Associated Press News